Mdoloris Medical Systems SAS reported it has developed an automated system for regulating perioperative pain based on continuous optimization of parasympathetic tone. Closed-loop control systems are still rare in the anesthesia space, but they provide greater reliability in achieving set objectives, reduce the risk of human error and free the anesthesiologist from the burden of manually adapting the administration of the various therapies required for surgery.
Researchers at West China Hospital, Sichuan University have identified remimazolam derivatives reported to be useful for the treatment of sedation and as anesthetics.
Cadent Therapeutics Inc. and Novartis AG have described cyclopental[c]pyrrol glutamate receptor ionotropic, NMDA 2B (GRIN2B; GluN2B) negative allosteric modulators reported to be useful for the treatment of pain, autism, tinnitus, anxiety disorders, Rett syndrome, Parkinson's disease, migraine and major depression.
Leitat Technological Center has patented 2,3-dihydro-1h-pyrrolo[3,2-b]pyridine derivatives acting as sigma non-opioid intracellular receptor 1 (SIGMAR1) and sigma intracellular receptor 2 (TMEM97) ligands reported to be useful for the treatment of pain, hyperalgesia, depression, anxiety and attention deficit hyperactivity disorder (ADHD).
Efforts at Abbvie Inc. to selectively target voltage-gated sodium channel subunit alpha Nav1.7 to treat pain led to the discovery of quinoline and quinolone agents and, through structure-activity relationship studies, the candidate product ABBV-318. While Nav1.7 potency could be achieved with earlier compounds, efforts were required to improve characteristics including hERG activity, pharmacokinetics and selectivity over Nav1.5, yielding compounds which blocked Nav1.7 as well as another target for treating pain, Nav1.8.
An artificial intelligence machine learning model that mines electronic health record data could help physicians fight the opioid epidemic by targeting non-opioid pain treatments to patients experiencing severe pain after surgery, according to new research presented at the Anesthesiology 2020 annual meeting.
HONG KONG – South Korean med-tech venture Recens Medical Inc. has secured ₩7 billion (US$6 million) in series B funding. Lb Investment Inc., Kb Securities Co. Ltd., Bnk Securities Co. Ltd., Hyundai Venture Investment Corp. and Lighthouse Combined Investment Co. Ltd. participated in the investment.
TORONTO – A Halifax, Nova Scotia-based med-tech company has patented a device that removes CO? from anesthetic equipment in the OR in a way that is safer, more long-lasting and environmentally friendlier than conventional chemical absorbers. The Memsorb is the brain child of anesthesiologist and Dmf Medical Inc. CMO Michael Schmidt who said anesthetizing patients during a long procedure can produce an amount of CO2 equivalent to 7,500 kilometers of travel in a car.